Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439122 | 0.85 | GSTP1 (0.53) | GPR84 | |
| SCHEMBL13049074 | 0.85 | SCN10A (0.39) | — | |
| SCHEMBL9262847 | 0.84 | PTGS2 (0.44) | RETPTGS2PTGER4SCN9AMMP2 | |
| SCHEMBL13439182 | 0.83 | CHEK2 (0.45) | SCN9A | |
| SCHEMBL3561860 | 0.81 | PTGS2 (0.40) | PTGS2PTGER4SCN9AMMP2MMP9 | |
| SCHEMBL3110262 | 0.79 | SLC2A1 (0.43) | PTGS2PTGER4SCN9AMMP2MMP9 | |
| SCHEMBL3556733 | 0.77 | SLC2A1 (0.48) | PTGS2PTGER4SCN9AMMP2MMP9 | |
| SCHEMBL3564002 | 0.76 | PTGER4 (0.45) | PTGS2PTGER4SCN9A | |
| SCHEMBL9267616 | 0.76 | SLC2A1 (0.39) | RETPTGS2SCN9A | |
| SCHEMBL3397344 | 0.75 | LMNA (0.43) | RETPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | claimed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | claimed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1967515-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2008-09-10 | — | — | EP | disclosed |
| EP-1967515-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2007138048-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP3A4, G6PD | RET 3989/4885PTGS2 1454/4885PTGER4 537/4885 |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP2C19, CYP3A4 | RET 2765/4885PTGS2 1115/4885PTGER4 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.